New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges |
Autore | Bakillah Ahmed |
Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2019 |
Descrizione fisica | 1 electronic resource (116 p.) |
Soggetto non controllato |
apolipoprotein
lipids risk stratification proprotein convertase subtilisin-kexin type 9 (PCSK9) vaspin sphingolipids PCSK9 ceramides atrial fibrillation circular RNA STEMI cholesterol lipoproteins cardiovascular disease (CVD) coronary artery bypass grafting atherosclerosis statin LDL subfractions acute kidney injury dyslipidemia gene expression NSTEMI NAFLD hyperlipidemia nonstatin cholesteryl ester transfer protein low-density lipoprotein cholesterol anacetrapib HDL acute coronary syndrome miRNA cardiovascular risk pleiotropic actions genetic ABCA1 sdLDL cardiovascular disease proprotein convertase subtilisin/kexin type 9 inclisiran reverse cholesterol transport sterol small interfering RNA (siRNA) RNA-binding proteins cardiovascular diseases NASH low-density lipoprotein-cholesterol (LDL-C) stroke nutrigenetics type 2 diabetes statins sphingomyelin hepatic fibrosis diabetes |
ISBN | 3-03921-677-5 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Altri titoli varianti | New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases |
Record Nr. | UNINA-9910367751903321 |
Bakillah Ahmed
![]() |
||
MDPI - Multidisciplinary Digital Publishing Institute, 2019 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
New Perspective in Atrial Fibrillation |
Autore | Guenancia Charles |
Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
Descrizione fisica | 1 electronic resource (224 p.) |
Soggetto topico | Medicine |
Soggetto non controllato |
postoperative atrial fibrillation
biomarkers coronary artery bypass grafting miRNA circRNA mtDNA SNPs atrial fibrillation acute myocardial infarction heart rate variability autonomic nervous system bleeding risk age left atrial appendage closure coronary artery disease prognosis anticoagulation antiplatelet therapy hypertension elderly prevention ganglionated plexi ablation dementia early-onset ischemic stroke risk factor new oral anticoagulants mitochondria cardiac remodeling pharmacotherapy electroporation pulsed field ablation cardiac heart arrhythmia NOAC VKA statin outcome mortality paroxysmal atrial fibrillation catheter ablation epicardial adipose tissue persistent atrial fibrillation posterior wall hybrid ablation convergent ablation atrial tachycardia mechanism spatiotemporal dispersion left atrial appendage occlusion BNP atrial remodeling atrial cardiopathy cardiac ablation irreversible electroporation |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910557507203321 |
Guenancia Charles
![]() |
||
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Pharmacogenetics to Avoid Adverse Drug Reactions |
Autore | López-Fernández Luis A |
Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (220 p.) |
Soggetto topico | Medicine |
Soggetto non controllato |
5-fluorouracil
capecitabine fluoropyrimidine thymidylate synthase thymidylate synthase enhancer region upstream stimulatory factor 1 adverse drug reactions pharmacogenomics epistasis random forest statin cardiovascular disease colorectal cancer personalised medicine toxicity (es)citalopram drug-gene-interaction drug-drug-interaction drug-drug-gene-interaction the PharmLines initiative antipsychotic agents pharmacogenetics cytochrome P-450 enzyme system psychotic disorders precision medicine direct oral anticoagulants clinical implementation atorvastatin SLCO1B1 HLA cutaneous adverse drug reaction SCAR genetic polymorphism antiepileptics CYP450 enzymes platelet reactivity single-nucleotide variants acute coronary syndrome clopidogrel genotype allele polymorphism HLA B CYP2C9*3 cutaneous adverse drug reactions (CADRs) anti-epileptic drugs (AEDS) phenytoin (PHT) genetic risk factors South India India cardiology adverse events guidelines |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910557610103321 |
López-Fernández Luis A
![]() |
||
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
The Prevention and Treatment of Atherosclerosis |
Autore | Kabłak-Ziembicka Anna |
Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (150 p.) |
Soggetto topico | Research & information: general |
Soggetto non controllato |
familial hypercholesterolemia
genetic screening atherosclerosis prevention early detection atherosclerosis cigarette smoking miR-27b peripheral artery disease subclinical atherosclerosis SCORE Framingham QRISK PROCAM cardiovascular risk pulse wave velocity intima media thickness malondialdehyde low-density lipoprotein high-risk plaque coronary computed tomography angiography statin cardiovascular risk factors heart failure major cardiac and cerebral ischemic events degenerative aortic stenosis risk stratification vascular resistance cardiovascular disease acute myocardial infarction intravascular imaging statins control-theoretic model logistic growth coronary artery disease fibrin clot fibrinolysis thromboembolism carotid intima-media complex carotid plaque major adverse cardiac and cerebral events prevention scores vitamin D myocardial infarction males Coronary Artery Surgery Study Score |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910566472203321 |
Kabłak-Ziembicka Anna
![]() |
||
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|